Welcome to our dedicated page for Collegium Pharmaceutical news (Ticker: COLL), a resource for investors and traders seeking the latest updates and insights on Collegium Pharmaceutical stock.
Collegium Pharmaceutical, Inc. reports developments for a diversified biopharmaceutical business focused on commercial medicines for serious medical conditions. Its recurring news centers on JORNAY PM for ADHD, a neuropsychiatry growth business, and a responsible pain management portfolio that includes BELBUCA, Xtampza ER, Nucynta products and Symproic.
Company updates also cover operating and financial results, investor presentations, real-world data from pain medications, branded ADHD awareness campaigns, capital deployment, credit facilities, material agreements, shareholder voting matters and governance disclosures.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) is set to release its first quarter 2023 financial results after market close on May 4, 2023. The announcement includes a live conference call and webcast scheduled for 4:30 p.m. ET, with dial-in numbers provided for U.S. and international participants.
The company focuses on developing specialty pharmaceuticals aimed at serious medical conditions. Collegium's commitment to improving patient lives underlines its strategic positioning within the pharmaceutical sector. The earnings call will offer insights into Collegium's financial performance and future outlook, attracting attention from investors keen on the company's financial metrics.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced participation in a fireside chat during the 22nd Annual Needham Healthcare Conference, scheduled for April 18, 2023, at 2:15 p.m. ET. The event will be held virtually from April 17-20, 2023. Investors can access the live webcast through the Investors section on Collegium's website. A replay will be available for 90 days post-event. Collegium is known for its commitment to enhancing the lives of those affected by serious medical conditions, with its headquarters based in Stoughton, Massachusetts.
Collegium Pharmaceutical (Nasdaq: COLL) reported record net revenue of $129.6 million for Q4 2022 and $463.9 million for FY 2022, compared to $27.4 million and $276.9 million respectively in the previous year. The company exited 2022 with a cash balance of $173.7 million and reaffirmed its 2023 guidance, projecting product revenues between $565 million and $580 million. Collegium implemented strategic initiatives, including acquiring BDSI, achieving $85 million in annual synergies, and resolving all 27 opioid-related lawsuits. The company also initiated a $100 million share repurchase program.